Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D50OLM
|
|||
| Drug Name |
INCB00928
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Anemia [ICD-11: 3A00-3A9Z; ICD-10: D50-D64] | Phase 2 | [1] | |
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 2 | [1] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 2 | [1] | ||
| Company |
Incyte
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Activin receptor-like kinase 2 (ALK-2) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04582539) To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma.. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Incyte. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.